Lupus (SLE): vizsgálatok itt: Kína
163 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou, Zhengzhou
- Életkor
- 5 év to 17 év
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - 2. fázisTaking peopleA Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
- Where
- Beijing, Shanghai
- Életkor
- 18 év to 65 év
- People
- 248
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07299422 - 1. fázisTaking peopleF182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 64
- Run by
- Shandong New Time Pharmaceutical Co., LTD
See details and how to joinNCT07829614 - Korai 1. fázisNot yet taking people in KínaSNC116 Therapy for Refractory Systemic Lupus Erythematosus
- Where
- Nanjing
- Életkor
- 18 év to 65 év
- People
- 28
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07748156 - 2. fázisTaking peopleTo Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
- Where
- Beijing, Changchun, Changzhi, Changzhou, Chengdu, Chongqing, Dalian, Ganzhou, Guangzhou, Guilin, Harbin, Huzhou, Jingzhou, Jining, Kunming, Langfang, Lanzhou, Linfen, Luoyang, Nanning, Pingxiang, Shenzhen, Shijiazhuang, Shiyan, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Yangzhou, Yichang, Yichun, Zhengzhou, Zhuzhou
- Életkor
- 18 év to 70 év
- People
- 120
- Run by
- Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT07447986 - No phaseTaking peopleHigh Quality Evidence of Chinese Lupus Nephritis (HELP)
- Where
- Guangzhou
- Életkor
- 14 év and over
- People
- 5000
- Run by
- Sun Yat-sen University
See details and how to joinNCT03001973 - 2/3. fázisNot yet taking people in KínaIvarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 294
- Run by
- Chinese SLE Treatment And Research Group
See details and how to joinNCT07814664 - 1. fázisTaking peopleClinical Study of Cizutamig in Systemic Lupus Erythematosus
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Luoyang, Nanchang, Shanghai, Shenyang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 47
- Run by
- Candid Therapeutics
See details and how to joinNCT07215663 - No phaseTaking peopleINTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
- Where
- Guangzhou, Hong Kong, Shenzhen, Zhongshan, Zhuhai
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06314282 - No phaseTaking peopleIM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- Peking University Third Hospital
See details and how to joinNCT06513429 - 3. fázisNot yet taking people in KínaA Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
- Where
- Beijing, Fuzhou, Guangzhou, Harbin, Luzhou, Nanchang, Nanjing, Shenyang, Tianjin, Ürümqi, Xi'an, Xuzhou, Yantai
- Életkor
- 18 év to 65 év
- People
- 70
- Run by
- Zhao Minghui
See details and how to joinNCT07767188 - Korai 1. fázisTaking peopleSafety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 36
- Run by
- Zhejiang University
See details and how to joinNCT06711146 - 2. fázisTaking peopleA Study of E6742 in Participants With Systemic Lupus Erythematosus
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Jiujiang, Kunming, Linfen, Luoyang, Nanchang, Nanjing, Nanning, Pingxiang, Shantou, Suzhou, Taiyuan, Xinxiang, Yichang, Yinchuan
- Életkor
- 18 év to 75 év
- People
- 256 worldwide
- Run by
- Eisai Co., Ltd.
See details and how to joinNCT07515014 - 1. fázisTaking peopleEfficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
- Where
- Hefei
- Életkor
- 18 év to 69 év
- People
- 30
- Run by
- Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT06801119 - 1. fázisNot yet taking people in KínaSafety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év to 69 év
- People
- 12
- Run by
- Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT07523282 - 2. fázisNot yet taking people in KínaA Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
- Where
- Changde, Changsha, Guilin, Handan, Huzhou, Jinhua, Linfen, Liupanshui, Loudi, Mianyang, Nanchong, Ningbo, Shanghai, Shenzhen, Shijiazhuang, Xuzhou, Zhongshan, Zhuzhou, Zibo
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Shanghai Escugen Biotechnology Co., Ltd
See details and how to joinNCT07760155 - 1. fázisTaking peopleIASO-782 in Systemic Lupus Erythematosus
- Where
- Hangzhou, Huzhou, Jiaxing
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Shanghai IASO Biotechnology Co., Ltd
See details and how to joinNCT07483346 - 1. fázisNot yet taking people in KínaA Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
- Where
- Chengdu
- Életkor
- 18 év to 65 év
- People
- 64
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07751315 - 1/2. fázisTaking peopleCD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
- Where
- Beijing
- Életkor
- 10 év to 65 év
- People
- 45
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06947460 - 4. fázisTaking peopleChildhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
- Where
- Beijing, Changchun, Changsha, Chongqing, Nanjing, Shanghai, Shenzhen
- Életkor
- 6 év to 18 év
- People
- 198
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07719140 - Korai 1. fázisNot yet taking people in KínaCD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680 - No phaseNot yet taking people in KínaApplication of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Nanjing University
See details and how to joinNCT07706998 - 1. fázisTaking peopleA Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 84
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06857214 - 2. fázisTaking peopleA Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
- Where
- Anyang, Beijing, Bengbu, Bozhou, Changchun, Changsha, Chongqing, Daqing, Guangzhou, Hangzhou, Jiangmen, Jingzhou, Lanzhou, Linfen, Nanchang, Nanjing, Nanning, Puyang, Shanghai, Shenzhen, Taizhou, Tianjin, Weifang, Wuhan, Xi’an, Xuchang, Yibin, Yichang, Zhengzhou, Zhuzhou, Zunyi
- Életkor
- 18 év to 74 év
- People
- 198
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07509892 - 1. fázisTaking peopleThe BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
- Where
- Nanjing
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Nanjing University School of Medicine
See details and how to joinNCT06285279